Advicenne Announces 51% Growth in Sibnayal Gross Sales in H1 2023 to almost €1.0 Million

Regulatory News:

Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announced that gross sales reached 2.2 million euros for the first half of 2023, up 23% on the previous year.

For the first time, and in line with the Company's strategic plan, gross sales growth was mainly driven by Sibnayal sales. Those posted a 128% increase in volume over the first six months of the year compared with the first half of 2022. In value terms, gross sales of Sibnayal rose by 51% over the same period to 0.96 million euros (vs. 0.64 million euros in first-half 2022). Sibnayal became the Group's leading product, ahead of Likozam and Levidcen with sales of 0.93 and 0.33 million euros respectively. Overall, gross sales for the Neurology franchise (Likozam and Levidcen) rose by more than 8% over the period.

The discrepancy between growth in value and volume is largely due to the implementation of partnerships and the transfer pricing structure. A more detailed analysis of sales shows an acceleration in half-yearly growth in both volume and value.

Gross sales (m€)	S1 2023	S1 2022	Growth
Sibnayal	0,96	0,64	+51%
Neurology	1,26	1,17	+8%
of which Likozam	0,93	0,87	+11%
of which Levidcen	0,33	0,30	+7%
Total	2,22	1,80	+23%

Didier Laurens, Chief Executive Officer of Advicenne, commented: "The first half of 2023 saw the implementation of our partnerships throughout Europe, and their first results. This first half is in line with our expectations, with more and more patients being treated across Europe and beyond; and very limited drop-out. It fits with our mission to meet unmet medical needs in rare diseases with drugs that significantly improve the daily lives of patients and their families.”